The case for low blood pressure targets

American Journal of Hypertension

Volumn 30, Issue 1, 2017, Pages 3-7

  Flack, John M ^a   Nolasco, Carlos ^a   Levy, Phillip ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Hypertension; SPRINT trial; Treatment recommendations

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIURETIC AGENT;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; BRAIN HEMORRHAGE; CONCEPTUAL FRAMEWORK; DATA BASE; EPIDEMIOLOGICAL DATA; FAINTNESS; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LACUNAR STROKE; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; BLOOD PRESSURE; DRUG EFFECTS; META ANALYSIS (TOPIC);

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85014893071     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpw087     Document Type: Review

References (24)

1. Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213:1143-1152.
2. Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension: influence of age, diastolic pressure and prior cardiovascular disease: further analysis of side effects. Circulation 1972; 45:991-1004.
3. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387:435-443.
4. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016; 387:957-967.
5. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
6. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103-2116.
7. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular outcomes according to systolic blood in patients with and without diabetes: An ACCOMPLISH substudy. J Clin Hypertens (Greenwich) 2016; 18:299-307.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
9. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
10. ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-2997.
11. SPS3 Investigators. Effects of blood pressure targets in patients with recent lacunar stroke. Lancet 2013; 382:507-515.
12. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
13. Ference BA, Julius S, Mahajan N, Levy PD, Williams KA Sr, Flack JM. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension 2014; 63:1182-1188.
14. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
15. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374:525-533.
16. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
17. Karmali KN, Ning H, Goff DC, Lloyd-Jones DM. Identifying individuals at risk for cardiovascular events across the spectrum of blood pressure levels. J Am Heart Assoc 2015; 4:e002126.
18. Liu K, Colangelo LA, Daviglus ML, Goff DC, Pletcher M, Schreiner PJ, Sibley CT, Burke GL, Post WS, Michos ED, Lloyd-Jones DM. Can antihypertensive treatment restore the risk of cardiovascular disease to ideal levels? The Coronary Artery Risk Development in Young Adults (CARADIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc 2015; 4:e002275.
19. Myers MG, Kaczorowski J, Dawes M, Godwin M. Automated office blood pressure measurement in primary care. Can Fam Physician 2014; 60:127-132.
20. Armstrong D, Matangi M, Brouillard D, Myers MG. Automated office blood pressure-being alone and not location is what matters most. Blood Press Monit 2015; 20:204-208.
21. Mancia G, Kjeldsen SE, Zappe DH, Holzhauer B, Hua TA, Zanchetti A, Julius S, Weber MA. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J 2016; 37:955-964.
22. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med 2013; 126:501-508.
23. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA; International Society on Hypertension in Blacks. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56:780-800.
24. Wright JT Jr, Agodoa LY, Appel L, Cushman WC, Taylor AL, Obegdegbe GG, Osei K, Reed J. New recommendations for treating hypertension in Black patients: evidence and/or consensus? Hypertension 2010; 56:801-803.